Epidemiology and Outcomes in a Linked Cohort of Cancer Pathology and Electronic Medical Records From the PHARMO Data Network
Author(s)
Nikita Jeswani, BA, MBA1, Ellie Iob, PHD2, Naomi Reimes, PHD2, Josine Kuiper, PhD3, Rinus Voorham, PHD4.
1Head of Sales, Lumanity, London, United Kingdom, 2PHARMO Lumanity, Utrecht, Netherlands, 3PHARMO Institute, Utrecht, Netherlands, 4Palga, Utrecht, Netherlands.
1Head of Sales, Lumanity, London, United Kingdom, 2PHARMO Lumanity, Utrecht, Netherlands, 3PHARMO Institute, Utrecht, Netherlands, 4Palga, Utrecht, Netherlands.
OBJECTIVES: Abstract summarises the top five cancer types for which pathological data are essential, highlighting the significance of using linked cancer data from the Netherlands Cancer Registry (NCR), pathology data from Dutch Pathology Registry (PALGA), and EMRs from PHARMO Data Network for studying targeted therapies.
METHODS: Cancer and pathology registries, combined with EMR from the PHARMO Data Network, were used to assess in-depth longitudinal data on cancer incidence, pathological profiles, and survival. We estimated the number of patients captured in this linked cohort and their survival between 2015-2022 for the top five cancers, summarising key pathological markers based on literature.
RESULTS: Breast Cancer:~30,000 patients are captured, with a 5-year survival rate of 41%. The human epidermal growth factor receptor 2 (HER2) mutation, found in ~4% of patients, is crucial as HER2-positive patients respond well to targeted therapies (e.g., trastuzumab). Colorectal Cancer:~27,000 patients are captured, with a 5-year survival rate of 33%. Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are present in ~40% of patients, while epidermal growth factor receptor (EGFR) overexpression occurs in 60-80% of tumors. KRAS mutations predict the efficacy of EGFR inhibitors. Lung Cancer:~28,000 patients are captured. Only 10% of lung cancer patients survive to year 5. EGFR mutations are associated with better responses to EGFR-tyrosine kinase inhibitors (TKIs), while KRAS mutations predict resistance. Skin Cancer:~40,000 patients are captured, with a 5-year survival rate of 33%. The B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation is found in ~50% of melanomas. BRAF inhibitors are effective in treating BRAF mutation-positive melanoma. Ovarian Cancer:~2,800 patients are captured, with a 5-year survival rate of 18%. BRCA1 and BRCA2 gene mutations increase ovarian cancer risk and are associated with better responses to platinum-based chemotherapy and poly-ADP ribose polymerase (PARP) inhibitors.
CONCLUSIONS: Combining cancer, pathology, and EMR data offers a robust platform for studying pathological markers and targeted therapies.
METHODS: Cancer and pathology registries, combined with EMR from the PHARMO Data Network, were used to assess in-depth longitudinal data on cancer incidence, pathological profiles, and survival. We estimated the number of patients captured in this linked cohort and their survival between 2015-2022 for the top five cancers, summarising key pathological markers based on literature.
RESULTS: Breast Cancer:~30,000 patients are captured, with a 5-year survival rate of 41%. The human epidermal growth factor receptor 2 (HER2) mutation, found in ~4% of patients, is crucial as HER2-positive patients respond well to targeted therapies (e.g., trastuzumab). Colorectal Cancer:~27,000 patients are captured, with a 5-year survival rate of 33%. Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are present in ~40% of patients, while epidermal growth factor receptor (EGFR) overexpression occurs in 60-80% of tumors. KRAS mutations predict the efficacy of EGFR inhibitors. Lung Cancer:~28,000 patients are captured. Only 10% of lung cancer patients survive to year 5. EGFR mutations are associated with better responses to EGFR-tyrosine kinase inhibitors (TKIs), while KRAS mutations predict resistance. Skin Cancer:~40,000 patients are captured, with a 5-year survival rate of 33%. The B-Raf proto-oncogene, serine/threonine kinase (BRAF) mutation is found in ~50% of melanomas. BRAF inhibitors are effective in treating BRAF mutation-positive melanoma. Ovarian Cancer:~2,800 patients are captured, with a 5-year survival rate of 18%. BRCA1 and BRCA2 gene mutations increase ovarian cancer risk and are associated with better responses to platinum-based chemotherapy and poly-ADP ribose polymerase (PARP) inhibitors.
CONCLUSIONS: Combining cancer, pathology, and EMR data offers a robust platform for studying pathological markers and targeted therapies.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EPH80
Topic
Epidemiology & Public Health, Methodological & Statistical Research, Real World Data & Information Systems
Disease
Genetic, Regenerative & Curative Therapies, Oncology